The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Precision BioSciences' patent application 13/245,607 (the '607 Application) regarding the engineered meganucleases.
The patent relates to methods of cleaving a target DNA site in a cell using an engineered meganuclease, utilizing as a part of Precision’s DNE genome engineering technology.
Precision BioSciences Scientific Development VP and the ‘607 application co-inventor Derek Jantz said they welcome the decision by the PTO allowing these claims, which cover their inventions of methods for cleaving DNA.
"Importantly, the claimed methods include the use of engineered features that are a key aspect of Precision’s award-winning DNE approach to genome engineering," Jantz said.